Get all your news in one place.
100's of premium titles.
One app.
Start reading
Evening Standard
Evening Standard
Business
Henry Saker-Clark

Novo Nordisk cuts sales and profits guidance amid obesity drug competition

Wegovy maker Novo Nordisk cut sales and profit guidance (James Manning/PA) - (PA Wire)

The drugmaker behind Ozempic and Wegovy has cut its sales and profit targets in the face of intense competition from other weight-loss and diabetes treatments.

Novo Nordisk warned over weaker-than-expected profits amid the recent growth of US rival Eli Lilly’s Mounjaro and Zepbound injection treatments.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.